Department of Pathology, St Mary’s Hospital, McGill University, Montreal, Canada.
Arch Pathol Lab Med. 2011 Feb;135(2):194-9. doi: 10.5858/2008-0421-SOR1.1.
Histologic and receptor data on breast carcinoma in Uganda are scarce. Estrogen receptor status is not routinely available. Breast cancer blocks from Uganda were studied in Montreal, Canada, and clinical correlations subsequently discussed in Kampala, Uganda.
To correlate histologic features (tumor type, histologic grade), receptor profile (estrogen receptor, progesterone receptor, and HER2/neu), and age in Ugandan women.
Pathology reports for 2000-2004 from Nsambya Hospital, reporting invasive breast carcinoma, provided 45 microscopically confirmed cases.
Seventy-three percent of patients were 50 years or younger. Histologic types were invasive ductal carcinoma (78%) and "good" prognosis types (11%). Overall 40% were grade 3, but 48% of invasive ductal carcinomas were grade 3. Estrogen receptor was positive in 60% overall and in 51% of invasive ductal carcinomas. HER2/neu was overexpressed in 11%; 36% were "triple" negative (estrogen receptor, progesterone receptor, HER2/neu negative).
Breast carcinoma in Ugandan women presents at a younger age and is histologically and by receptor profile more aggressive than carcinoma in Caucasian women.
乌干达的乳腺癌组织学和受体数据很少。雌激素受体状态通常无法获得。在加拿大蒙特利尔研究了来自乌干达的乳腺癌块，并随后在乌干达坎帕拉讨论了临床相关性。
在乌干达妇女中，将组织学特征（肿瘤类型、组织学分级）、受体谱（雌激素受体、孕激素受体和 HER2/neu）和年龄进行关联。
从 Nsambya 医院 2000-2004 年的病理报告中，提供了 45 例经显微镜证实的浸润性乳腺癌病例。
73%的患者年龄在 50 岁或以下。组织学类型为浸润性导管癌（78%）和“良好”预后类型（11%）。总体而言，40%为 3 级，但 48%的浸润性导管癌为 3 级。雌激素受体阳性率总体为 60%，浸润性导管癌为 51%。HER2/neu 过表达率为 11%；36%为“三阴性”（雌激素受体、孕激素受体、HER2/neu 阴性）。
乌干达妇女的乳腺癌发病年龄更年轻，组织学和受体谱比白人妇女的乳腺癌更具侵袭性。
